Myriad Genetics | MYGN - Selling And Administration Expenses


Myriad Genetics reported $122.3M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agilent USD 465M 11M Mar/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Bio-Rad Laboratories USD 221M 14.2M Dec/2025
Bruker USD 242.1M 5.1M Mar/2026
Danaher USD 1.86B 166M Mar/2026
Illumina USD 272M 11M Mar/2026
J&J USD 6.03B 719M Mar/2026
Mettler Toledo International USD 258.33M 1.5M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
OraSure Technologies USD 13.21M 3.29M Dec/2025
Pacific Biosciences Of California USD 37.24M 25.68M Dec/2025
Quest Diagnostics USD 504M 0 Mar/2026
Quidel USD 199.3M 4.9M Mar/2026
Repligen USD 76.54M 2.17M Mar/2026
Revvity USD 253.88M 2.15M Mar/2026
Standard Biotools USD 21.55M 5.05M Dec/2025
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Waters USD 394M 153.99M Mar/2026